## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIESM

## OMB APPROVAL OMB 3235-0104 Expires: December 31, 2014 Estimated average burden hours per 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person <sup>*</sup>	2. Date of Event Requiring	3. Issuer Name <b>and</b> Ticker or Trading Sy CYTOKINETICS INC [CYTK]	mbol
HOMCY CHARLES J	Statement (Month/Day/Year) 04/28/2004	to Issuer	5. If Amendment, Date of Original Filed (Month/Day/Year)
(Last) (First) (Middle) C/O MILLENNIUM PHARMACEUTICALS, INC., 75 SIDNEY STREET (Street) CAMBRIDGE MA 02139 (City) (State) (Zip)	04/20/2004		6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - I	Non-Derivative Securities Benefi	cially Owned	
1. Title of Security (Instr. 4)	2. Amount of Securities Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

			e Securities Benefic nts, options, conver				
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Excercise	Form: Direct (D)	6. Nature of Indirect Beneficial Ownership
	Date Exercisable	Expiration Date	Title	Amount or Number of SharesM	Price of Derivative Security	or Indirect (I) (Instr. 5)	(Instr. 5)
Employee Stock Option (right to buy)	03/19/2003(1)	03/19/2013	Common Stock	30,000 (2)	\$ 0.6	D	
Employee Stock Option (right to buy)	05/21/2003(1)	05/21/2013	Common Stock	12,500 (3)	\$ 0.6	D	

## **Explanation of Responses:**

1. Option immediately exercisable upon Date of Grant.

2. The shares subject to the Option shall be released from the Company's Repurchase Option per the following vesting schedule: 1/36th after one month (March 13, 2003) and 1/36th per month thereafter.

3. The shares subject to the Option shall be released from the Company's Repurchase Option per the following vesting schedule: 1/24th after one month (April 3, 2003) and 1/24th per month thereafter.

<u>/s/ James H. Sabry, by</u> power of attorney	04/28/2004
** Signature of Reporting Person	Date
/s/ Robert I. Blum, by	04/28/2004
power of attorney	01/20/2001

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Persons who respond to the collection of information contained in this form are not required to respond unless the form

displays a currently valid OMB Number.

The undersigned, as a Section 16 reporting person of Cytokinetics, Incorporated (the "Company"), hereby constitutes and appoints James H. Sabry and Robert I. Blum, and each of them, the undersigned's true and lawful attorney-in-fact to:

- 1. complete and execute Forms 3, 4 and 5 and other forms and all amendments thereto as such attorney-in-fact shall in his or her discretion determine to be required or advisable pursuant to Section 16 of the Securities Exchange Act of 1934 (as amended) and the rules and regulations promulgated thereunder, or any successor laws and regulations, as a consequence of the undersigned's ownership, acquisition or disposition of securities of the Company; and
- do all acts necessary in order to file such forms with the Securities and Exchange Commission, any securities exchange or national association, the Company and such other person or agency as the attorney-in-fact shall deem appropriate.

The undersigned hereby ratifies and confirms all that said attorneys-in-fact and agents shall do or cause to be done by virtue hereof. The undersigned acknowledges that the foregoing attorneys-in-fact, in serving in such capacity at the request of the undersigned, are not assuming, nor is the Company assuming, any of the undersigned's responsibilities to comply with Section 16 of the Securities Exchange Act of 1934 (as amended).

This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4, and 5 with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the Company and the foregoing attorneys-in-fact.

IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 24th day of April, 2004.

Signature: /s/ Charles Homcy

Print Name: Charles J. Homcy